Mobile-enhanced Group CBT for Adolescents at Risk Severe Mood Disorders
Study Details
Study Description
Brief Summary
Although cognitive-behavioral therapy (CBT) has shown efficacy in reducing symptoms and rates of mood relapse in adolescents at high risk for severe mood disorders (SMD; i.e., bipolar I/II disorder and recurrent or unremitting major depression), a significant limitation to the CBT's efficacy is the low rate of participant adherence to the prescribed between-session homework tasks. Mobile health applications have the potential to improve adherence to and acceptance of treatment through embedded treatment content, skill-practice, thought and symptom monitoring, all of which are facilitated by reward contingencies and notifications. This study examines whether a mobile application-enhanced CBT can improve participant adherence and treatment acceptance for adolescents at high risk for SMD.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Cognitive behavioral therapy (CBT)
|
Behavioral: Cognitive behavioral therapy (CBT)
Group-based transdiagnostic cognitive-behavioral treatment
|
Outcome Measures
Primary Outcome Measures
- Change in weekly participant adherence [3-month study period]
Clinician-rated based on participant report
- Subjective app usability scale [Measured at the end of the 3-month study period]
Participant's subjective experience of mobile application. Scores range from 0 - 36 (6 7-point Likert scale items) with higher scores indicating greater subjective usability and acceptability of app
- Psychosocial compliance scale [3-month study period]
Clinician-rated of participant overall treatment compliance. Scores range from 17-85 (17 5-point Likert scale items) with higher scores indicating greater treatment compliance
- Participant app usage [3-month study period]
Frequency of participants' app usage
Secondary Outcome Measures
- Children's Depression Rating Scale, Revised [Measured prior to treatment (0 months) and the end of the three-month study period.]
Measures depressive symptom severity. Scores range from 17-113 (14 7-point items and 3 5-point items) with higher scores indicating greater depressive severity.
- Young Mania Rating Scale [Measured prior to treatment (0 months) and the end of the three-month study period.]
Measure manic symptom severity. Scores range from 0-60 (7 5-point items and 4 9-point items) with higher scores indicating greater manic severity.
- Clinical Global Assessment Scale [Measured prior to treatment (0 months) and the end of the three-month study period.]
Measures overall functioning on a 1-100 scale, with higher scores indicating better functioning.
- Clinical Global Impression [Measured prior to treatment (0 months) and the end of the three-month study period.]
Measures overall clinical functioning from 1-7, with higher scores indicating greater psychiatric severity.
- Symptom Checklist 90 [Measured prior to treatment (0 months) and the end of the three-month study period.]
Participant-reported psychiatry symptoms. Scores range from 0 - 360 (90 5-point Likert items) with higher scores indicating greater symptom severity.
- Depression Anxiety & Stress Scale [Measured prior to treatment (0 months) and the end of the three-month study period.]
Participant reported mood, anxiety and stress. Scores range from 0 - 63 (21 4-point items) with higher scores indicating greater distress.
- KINDL [Measured prior to treatment (0 months) and the end of the three-month study period.]
Quality of life measure. Scores range from 0 - 120 (30 5-point items) with higher scores indicating poorer quality of life.
- Depression Anxiety & Stress Scale [Measured prior to treatment (0 months) and the end of the three-month study period.]
Parent reported mood, anxiety and stress. Scores range from 0 - 63 (21 4-point items) with higher scores indicating greater distress.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Meet DSM-5 criteria for at least one past major depressive disorder, persistent depressive disorder, or unspecified bipolar disorder
-
Be 13-17 years old
-
English speaking and able to complete written questionnaires
-
Ability to attend pre-determined group session time(s)
-
Access to a smartphone to engage with the study app
-
Medication usage is acceptable, but not required
Exclusion Criteria:
-
Regular use or current abuse of a psychoactive drug
-
Evidence of behavioral problems that are thought to interfere with group treatment
-
Suicidality that requires more intensive treatment
-
Meeting DSM 5 criteria for bipolar I or II disorder, a psychotic disorder, or significant psychiatric symptoms (e.g., self-injurious behavior) that require more intensive treatment
-
Concurrent participation in cognitive-behavioral therapy
-
Inability to travel to study sessions and assessments
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | UCLA Semel Institute | Los Angeles | California | United States | 90095-8353 |
Sponsors and Collaborators
- University of California, Los Angeles
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 21-000036